Evidence-based practice in Behçet's disease: Identifying areas of unmet need for 2014

Orphanet Journal of Rare Diseases

Volumn 9, Issue 1, 2014, Pages

  Barry, Robert J ^a,b   Markandey, Bharat ^c   Malhotra, Rahul ^c   Knott, Henry ^c   Joji, Nikita ^c   Mubin, Mohammed ^c   Denniston, Alastair K ^a,b,d   Murray, Phillip I ^a,b,d  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^d CITY HOSPITAL   (United Kingdom)

Author keywords

Beh et's disease; Evidence based medicine; Systematic review; Therapy

Indexed keywords

BEHCET SYNDROME; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 84893207539     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-9-16     Document Type: Article

References (76)

1. Evidence based medicine: what it is and what it isn't. Sackett D, Rosenberg W, Gray JA, Haynes RB, Richardson WS, BMJ 1996 312 71 72 10.1136/bmj.312.7023.71 8555924
2. Critical appraisal of published research: introductory guidelines. Fowkes FG, Fulton PM, BMJ 1991 302 1136 1140 10.1136/bmj.302.6785.1136 2043787
3. A new system for grading recommendations in evidence based guidelines. Harbour R, Miller J, BMJ 2001 323 334 336 11498496 (Pubitemid 32744465)
4. Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51. Direskeneli H, Ann Rheum Dis 2001 60 11 996 1002 10.1136/ard.60.11.996 11602462 (Pubitemid 32990034)
5. Behçet's syndrome. Yazici Y, Yurdakul S, Yazici H, Curr Rheumatol Rep 2010 12 6 429 435 10.1007/s11926-010-0132-z 20862570
6. Behçet's Disease. Sakane T, Takeno M, Suzuki N, Inaba G, NEJM 1999 341 17 1284 1291 10.1056/NEJM199910213411707 10528040 (Pubitemid 29489745)
7. Evaluation of current therapeutic strategies in Behçet's disease. Alexoudi I, Kapsimali V, Vaiopoulos A, Kanakis M, Vaiopoulos G, Clin Rheumatol 2011 30 2 157 163 10.1007/s10067-010-1566-4 20842513
8. Anti-TNF agents for Behcet's Disease: analysis of published data on 369 patients. Arida A, Fragiadaki K, Giavri E, Sfikakis PP, Semin Arthritis Rheum 2011 41 1 61 70 10.1016/j.semarthrit.2010.09.002 21168186
9. Criteria for diagnosis of Behçet's disease. Wechsler B, Davatchi F, Mizushima Y, Hamza M, Dilsen N, Kansu E, Yazici H, Barnes CG, Chamberlain MA, James DG, Lehner T, O'Duffy JD, Rigby AS, Gregory J, Silman AJ, Lancet 1990 335 1078 1080 1970380
10. Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis. Sakai T, Watanabe H, Kuroyanagi K, Akiyama G, Okano K, Kohno H, Tsuneoka H, Br J Ophthalmol 2013 97 3 338 342 10.1136/bjophthalmol-2012-302515 23314623
11. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V, Androudi S, Ophthalmology 2013 120 4 777 787 10.1016/j.ophtha.2012.09.040 23290985
12. Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy. Yoshida A, Kaburaki T, Okinaga K, Takamoto M, Kawashima H, Fujino Y, Jpn J Ophthalmol 2012 56 6 536 543 10.1007/s10384-012-0182-z 23053631
13. Ocular Behçet's Disease Research Group Of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Okada AA, Goto H, Ohno S, Mochizuki M, Arch Ophthalmol 2012 130 5 592 598 10.1001/archophthalmol.2011.2698 22652845
14. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study. Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP, Rheumatology 2011 50 3 593 597 10.1093/rheumatology/keq366 21097877
15. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs. Giardina A, Ferrante A, Ciccia F, Vadalà M, Giardina E, Triolo G, Rheumatol Int 2011 31 1 33 37 10.1007/s00296-009-1213-z 19859715
16. Azathioprine in severe uveitis of Behçet's disease. Saadoun D, Wechsler B, Terrada C, Hajage D, Le Thi HD, Resche-Rigon M, Cassoux N, Le Hoang P, Amoura Z, Bodaghi B, Cacoub P, Arthritis Care Res 2010 62 12 1733 1738 10.1002/acr.20308
17. Effects of atorvastatin and lisinopril on endothelial dysfunction in patients with Behçet's disease. Inanc MT, Kalay N, Heyit T, Ozdogru I, Kaya MG, Dogan A, Duran M, Kasapkara HA, Gunebakmaz O, Borlu M, Yarloglues M, Oguzhan A, Echocardiography 2010 27 8 997 1003 10.1111/j.1540-8175.2010.01180.x 20545993
18. Pimecrolimus versus placebo in genital aphthous ulcers of Behcet's disease: a randomized double-blind controlled trial. Chams-Davatchi C, Barikbin B, Shahram F, Nadji A, Moghaddassi M, Yousefi M, Davatchi F, Int J Rheum Dis 2010 13 3 253 258 10.1111/j.1756-185X.2010.01531.x 20704623
19. Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A, Chams-Davatchi C, Akhlaghi M, Faezi T, Naderi N, Int J Rheum Dis 2010 13 3 246 252 10.1111/j.1756-185X.2010.01546.x 20704622
20. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M, Br J Ophthalmol 2010 94 3 284 288 10.1136/bjo.2009.158840 19692382
21. Relationship between periodontal parameters and Behçet's disease and evaluation of different treatments for oral recurrent aphthous stomatitis. Arabaci T, Kara C, Ciçek Y, J Periodontal Res 2009 44 6 718 725 10.1111/j.1600-0765.2008.01183.x 19076988
22. Low-dose natural human interferon-alpha lozenges in the treatment of Behçet's syndrome. Kiliç H, Zeytin HE, Korkmaz C, Mat C, Gül A, Coşan F, Dinç A, Simşek I, Süt N, Yazici H, Rheumatology 2009 48 11 1388 1391 10.1093/rheumatology/kep237 19717547
23. Effectiveness and safety of endovascular aneurysm treatment in patients with vasculo-Behçet disease. Kim WH, Choi D, Kim JS, Ko YG, Jang Y, Shim WH, J Endovasc Ther 2009 16 5 631 636 10.1583/09-2812.1 19842735
24. Treatment with levamisole and colchicine can result in a significant reduction of IL-6, IL-8 or TNF-alpha level in patients with mucocutaneous type of Behcet's disease. Sun A, Wang YP, Chia JS, Liu BY, Chiang CP, J Oral Pathol Med 2009 38 5 401 405 10.1111/j.1600-0714.2009.00774.x 19434815
25. The close association between dental and periodontal treatments and oral ulcer course in behcet's disease: a prospective clinical study. Karacayli U, Mumcu G, Simsek I, Pay S, Kose O, Erdem H, Direskeneli H, Gunaydin Y, Dinc A, J Oral Pathol Med 2009 38 5 410 415 10.1111/j.1600-0714.2009.00765.x 19320802
26. Randomized trial of pimecrolimus cream plus colchicine tablets versus colchicine tablets in the treatment of genital ulcers in Behçet's disease. Köse O, Dinç A, Simşek I, Dermatology 2009 218 2 140 145 10.1159/000182257 19060462
27. Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial. Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, Shahram F, Nadji A, Shams H, Chams-Davatchi C, Mod Rheumatol 2009 19 5 542 549 19597921
28. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Tabbara KF, Al-Hemidan AI, Am J Ophthalmol 2008 146 6 845 850 10.1016/j.ajo.2008.09.010 18929351
29. Behçet's disease: comparing 3 decades of treatment response at the National Eye Institute. Kump LI, Moeller KL, Reed GF, Kurup SK, Nussenblatt RB, Levy-Clarke GA, Can J Ophthalmol 2008 43 4 468 472 10.3129/i08-080 18711463
30. Interrelated modulation of endothelial function in Behcet's disease by clinical activity and corticosteroid treatment. Protogerou AD, Sfikakis PP, Stamatelopoulos KS, Papamichael C, Aznaouridis K, Karatzis E, Papaioannou TG, Ikonomidis I, Kaklamanis P, Mavrikakis M, Lekakis J, Arthritis Res Ther 2007 9 5 90 10.1186/ar2289 17845731 (Pubitemid 350020814)
31. Lactobacilli lozenges in the management of oral ulcers of Behçet's syndrome. Tasli L, Mat C, De Simone C, Yazici H, Clin Exp Rheumatol 2006 24 3 83 S86 Erratum in: Clin Exp Rheumatol. 2007, 25 (3): 507-8 17067433
32. Oral zinc sulfate in the treatment of Behcet's disease: a double blind cross-over study. Sharquie KE, Najim RA, Al-Dori WS, Al-Hayani RK, J Dermatol 2006 33 8 541 546 10.1111/j.1346-8138.2006.00128.x 16923135 (Pubitemid 44154792)
33. A double-blind trial of depot corticosteroids in Behçet's syndrome. Mat C, Yurdakul S, Uysal S, Gogus F, Ozyazgan Y, Uysal O, Fresko I, Yazici H, Rheumatology 2006 45 3 348 352 16263779 (Pubitemid 43372853)
34. Colchicine and benzathine penicillin in the treatment of Behçet disease: a case comparative study. Al-Waiz MM, Sharquie KE, A-Qaissi MH, Hayani RK, Dermatol Online J 2005 11 3 3
35. Vitrectomy for persistent panuveitis in Behçet's disease. Ahn JK, Chung H, Yu HG, Ocul Immunol Inflamm 2005 13 6 447 453 10.1080/09273940591004232 16321889 (Pubitemid 41769983)
36. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, Hamuryudan V, Yazici H, J Rheumatol 2005 32 1 98 105 15630733 (Pubitemid 40092599)
37. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial. Kötter I, Vonthein R, Zierhut M, Eckstein AK, Ness T, Günaydin I, Grimbacher B, Blaschke S, Peter HH, Stübiger N, Semin Arthritis Rheum 2004 33 5 311 319 10.1016/j.semarthrit.2003.09.005 15079762 (Pubitemid 38496040)
38. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, Markomichelakis N, Ann Intern Med 2004 140 5 404 406 14996689 (Pubitemid 38268925)
39. Abdominal aortic aneurysm in Behçet's disease: new treatment options for an old and challenging problem. Nitecki SS, Ofer A, Karram T, Schwartz H, Engel A, Hoffman A, Isr Med Assoc J 2004 6 3 152 155 15055270 (Pubitemid 38380191)
40. Clinical study on therapeutic effect of acupuncture on Behcet's disease. Yu P, Bai H, Chen L, Zhang W, Xia Y, Wu G, J Tradit Chin Med 2003 23 4 271 273 14719295 (Pubitemid 41238386)
41. Evaluation of the effect of acetazolamide on cystoid macular oedema in patients with Behcet's disease. Lashay AR, Rahimi A, Chams H, Davatchi F, Shahram F, Hatmi ZN, Khalkhali H, Beigi B, Eye 2003 17 6 762 766 10.1038/sj.eye.6700464 12928692 (Pubitemid 37120971)
42. Interferon alfa-2a in the treatment of ocular Adamantiades- Behçet's disease. Krause L, Turnbull JR, Torun N, Pleyer U, Zouboulis CC, Foerster MH, Adv Exp Med Biol 2003 528 511 519 12918754
43. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double-blind, placebo-controlled study. Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, Nakamura S, Tanaka S, Kogure M, Mizushima Y, Drugs R D 2003 4 1 19 28 10.2165/00126839-200304010-00002 12568631 (Pubitemid 37062641)
44. Dapsone in Behçet's disease: a double-blind, placebo-controlled, cross-over study. Sharquie KE, Najim RA, Abu-Raghif AR, J Dermatol 2002 29 5 267 279 12081158 (Pubitemid 34742240)
45. Short-term chlorambucil for refractory uveitis in Behcet's disease. Mudun BA, Ergen A, Ipcioglu SU, Burumcek EY, Durlu Y, Arslan MO, Ocul Immunol Inflamm 2001 9 4 219 229 10.1076/ocii.9.4.219.3957 11935432 (Pubitemid 34286623)
46. A double-blind trial of colchicine in Behçet's syndrome. Yurdakul S, Mat C, Tüzün Y, Ozyazgan Y, Hamuryudan V, Uysal O, Senocak M, Yazici H, Arthritis Rheum 2001 44 11 2686 2692 10.1002/1529-0131(200111)44: 11<2686::AID-ART448>3.0.CO;2-H 11710724 (Pubitemid 33049346)
47. Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet's disease. Adler YD, Mansmann U, Zouboulis CC, Dermatology 2001 203 4 322 324 10.1159/000051781 11752821 (Pubitemid 34045195)
48. Ciclosporin microemulsion preconcentrate treatment of patients with Behçet's disease. Fujino Y, Joko S, Masuda K, Yagi I, Kogure M, Sakai J, Usui M, Kotake S, Matsuda H, Ikeda E, Mochizuki M, Nakamura S, Ohno S, Jpn J Ophthalmol 1999 43 4 318 326 10.1016/S0021-5155(99)00025-8 10482480 (Pubitemid 29329393)
49. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study. Alpsoy E, Er H, Durusoy C, Yilmaz E, Arch Dermatol 1999 135 5 529 532 10328192 (Pubitemid 29222295)
50. Effects of interferon-alpha2a treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis factor-alpha2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behçet's disease. Kosar A, Haznedaroglu S, Karaaslan Y, Büyükasik Y, Haznedaroglu IC, Ozath D, Sayinalp N, Ozcebe O, Kirazli S, Dündar S, Rheumatol Int 1999 19 1-2 11 14 10.1007/s002960050091 10651074 (Pubitemid 30025679)
51. Treatment of Adamantiades-Behçet disease with systemic interferon alfa. Zouboulis CC, Orfanos CE, Arch Dermatol 1998 134 8 1010 1016 9722733 (Pubitemid 28385325)
52. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H, Ann Intern Med 1998 128 6 443 450 10.7326/0003-4819-128-6-199803150- 00004 9499327
53. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease. Calgüneri M, Ertenli I, Kiraz S, Erman M, Celik I, Dermatology 1996 192 2 125 128 10.1159/000246336 8829493
54. A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behçet's disease and allied conditions. Sakane T, Mochizuki M, Inaba G, Masuda K, Ryumachi 1995 35 5 802 813 8594659
55. Inefficacy of azapropazone in the acute arthritis of Behçet's syndrome: a randomized, double blind, placebo controlled study. Moral F, Hamuryudan V, Yurdakul S, Yazici H, Clin Exp Rheumatol 1995 13 4 493 495 7586783
56. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Gardner-Medwin JM, Smith NJ, Powell RJ, Ann Rheum Dis 1994 53 12 828 832 10.1136/ard.53.12.828 7864692
57. Systemic interferon alpha 2b treatment in Behçet's syndrome. Hamuryudan V, Moral F, Yurdakul S, Mat C, Tüzün Y, Ozyazgan Y, Direskeneli H, Akoglu T, Yazici H, J Rheumatol 1994 21 6 1098 1100 7932420 (Pubitemid 24182284)
58. Visual prognosis in patients with Behçet's disease receiving colchicine, systemic corticosteroid or cyclosporin. Hayasaka S, Kawamoto K, Noda S, Kodama T, Ophthalmologica 1994 208 4 210 213 10.1159/000310490 7970549 (Pubitemid 24259789)
59. Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Ozyazgan Y, Yurdakul S, Yazici H, Tüzün B, Işçimen A, Tüzün Y, Aktunç T, Pazarli H, Hamuryudan V, Müftüoǧlu A, Br J Ophthalmol 1992 76 4 241 243 10.1136/bjo.76.4.241 1390495
60. Inefficacy of topical alpha interferon in the treatment of oral ulcers of Behçet's syndrome: a randomized, double blind trial. Hamuryudan V, Yurdakul S, Rosenkaimer F, Yazici H, Br J Rheumatol 1991 30 5 395 396
61. Desensitization by autologous saliva and Behçet's disease. Benamour S, Bennis R, Messoudi M, Zaoui A, Amor B, Rev Med Interne 1991 12 5 339 342 10.1016/S0248-8663(05)80843-4 1771312
62. Effect of cyclosporine A on the hearing loss in Behçet's disease. Elidan J, Levi H, Cohen E, BenEzra D, Ann Otol Rhinol Laryngol 1991 100 6 464 468 2058987
63. Long-term effects of cyclophosphamide and colchicine treatment in Behçet's disease. Kazokoglu H, Saatçi O, Cuhadaroglu H, Eldem B, Ann Ophthalmol 1991 23 4 148 151 2064258
64. Treatment of Behçet disease with indomethacin. Simsek H, Dundar S, Telatar H, Int J Dermatol 1991 30 1 54 57 10.1111/j.1365-4362.1991.tb05883.x 1993568
65. A controlled trial of azathioprine in Behçet's syndrome. Yazici H, Pazarli H, Barnes CG, Tüzün Y, Ozyazgan Y, Silman A, Serdaroǧlu S, Oǧuz V, Yurdakul S, Lovatt GE, Yazici B, Somani S, Müftüoǧlu A, N Engl J Med 1990 322 5 281 285 10.1056/NEJM199002013220501 2404204 (Pubitemid 20046329)
66. Topical alpha interferon in the treatment of oral ulcers in Behçet's syndrome: a preliminary report. Hamuryudan V, Yurdakul S, Serdaroglu S, Tüzün Y, Rosenkaimer F, Yazici H, Clin Exp Rheumatol 1990 8 1 51 54 (Pubitemid 20158227)
67. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G, Lancet 1989 1 8647 1093 1096 2566048 (Pubitemid 19128039)
68. Treatment with acyclovir does not affect orogenital ulcers in Behçet's syndrome: a randomized double-blind trial. Davies UM, Palmer RG, Denman AM, Br J Rheumatol 1988 27 4 300 302 10.1093/rheumatology/27.4.300 3044474
69. Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome. BenEzra D, Cohen E, Chajek T, Friedman G, Pizanti S, de Courten C, Harris W, Transplant Proc 1988 20 3 Suppl 4 136 143
70. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kotter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stubiger N, Yurdakul S, Yazici H, Ann Rheum Dis 2009 68 10 1528 1534 10.1136/ard.2008.087957 18420940
71. Development of consensus statements for the diagnosis and management of intestinal Behçet's disease using a modified Delphi approach. Kobayashi K, Ueno F, Bito S, Iwao Y, Fukushima T, Hiwatashi N, Masahiro I, Bun-Ei I, Takahide M, Toshiyuki M, Takayuki M, Akira S, Mitsuhiro T, Toshifumi H, J Gastroenterol 2007 42 737 745 10.1007/s00535-007-2090-4 17876543 (Pubitemid 47456761)
72. Developing a strategy for the management of rare diseases. Taylor CM, Karet Frankl FE, BMJ 2012 344 2417 10.1136/bmj.e2417 22498954
73. Representation of rare diseases in health information systems: the orphanet approach to serve a wide range of end users. Rath A, Olry A, Dhombres F, Brandt MM, Urbero B, Ayme S, Hum Mutat 2012 33 5 803 808 10.1002/humu.22078 22422702
74. EULAR recommendations for the management of Behçet disease. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kotter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stubiger N, Yurdakul S, Yazici H, Ann Rheum Dis 2008 67 12 1656 1662 10.1136/ard.2007.080432 18245110
75. New evidence-based treatment approach in Behçet's disease. Alpsoy E, Patholog. Res. Int. 2012 2012 871019 22007346
76. Pharmacotherapy for Behçet's syndrome. Saenz A, Ausejo M, Shea B, Ga W, Welch V, Tugwell P, Cochrane Database Syst Rev 1998 3 Suppl 4 ? Art No.: CD001084. DOI: 10.1002/14651858.CD001084